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Echinococcosis (hydatid disease) is caused by the larvae of dog
and fox tapeworms (cestodes) of the genusEchinococcus (family
Taeniidae).1-3This zoonosis is characterised by long term growth
of metacestode (hydatid) cysts in humans and mammalian
intermediate hosts. The two major species that infect humans
are E granulosus and E multilocularis, which cause cystic
echinococcosis (CE) and alveolar echinococcosis (AE). A few
reported cases of polycystic echinococcosis in Central and South
America are caused by E vogeli and E oligarthrus.2 w1 w2 The
clinical potential of two other Echinococcus species (E shiquicus
and E felidis) is unknown.1 2
Cystic echinococcosis (CE) and alveolar echinococcosis (AE)
are serious chronic diseases with poor prognosis and high
mortality if managed inadequately.1-3 Of the estimated two to
three million cases of echinococcosis globally, most are cystic.2 4
Published reports and the Office International des Epizooties
databases suggest that the global burden for human CE exceeds
one million disability adjusted life years (DALYs), resulting in
a loss of $760m (£490m; €612m) a year,4 although these figures
are probably underestimates.2 Case series and small clinical
trials show a mortality rate of 2-4% for CE, but this increases
markedly with poor treatment and care.5 6 There are 0.4 million
cases of human AE, and survival analysis has shown that, if
untreated or if treatment is limited, mortality exceeds 90% 10-15
years after diagnosis.5 7 About 18 000 new cases of AE occur
annually, with a total annual burden of 666 434 DALYs.8
Here, we introduce the Echinococcus parasites and the diseases
they cause, and we discuss current methods for the diagnosis,
treatment, and management of both types of echinococcosis.
The life cycle characteristics of Echinococcus spp and the causes
and immunology of echinococcosis have been described
extensively.1-3 9-14 w3-w16
Where and how is echinococcosis
acquired?
Figure 1⇓ shows the distribution of echinococcosis, according
to statistics from the World Health Organization. E granulosus
occurs worldwide, with high endemic areas concentrated in
north east Africa, South America, and Eurasia.10 12 E
multilocularis is restricted to the northern hemisphere.10 12 Figure
2⇓ illustrates the E granulosus and E multilocularis life cycles
and shows how humans become infected. Human co-infection
with E granulosus and Emultilocularis is not common, although
these two species are co-endemic in some specific foci, notably
the northwest of the People’s Republic of China.10 Figure 3⇓ is
an ultrasound image of a patient with both types of
echinococcosis.
What are the clinical features of
echinococcosis?
Most (>90%) CE cysts occur in liver, lung, or both organs.12 w17
In general, the initial stages of CE do not cause
symptoms—small cysts can remain asymptomatic for many
years.1 Because of the parasite’s slow growth most cases are
diagnosed in adults.3 The onset of symptoms depends on the
infected organ, the size and position of the cyst(s), their effect
on the organ and adjacent tissues, and complications arising
from the rupture of a cyst or a secondary infection.1 12Recurrent
(secondary) CE can arise after primary cyst surgery, owing to
spillage of the cyst contents, or if there is spontaneous or trauma
induced cyst rupture and release of larvae, which can grow into
secondary cysts.10 Leakage or rupture of CE cysts can induce
systemic immunological reactions and other complications,
including cholangitis.1 12
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Summary points
Echinococcosis is a parasitic zoonosis caused by Echinococcus cestode worms
The two major species of medical importance are Echinococcus granulosus and E multilocularis, which cause cystic echinococcosis
(CE) and alveolar echinococcosis (AE), respectively
CE and especially AE are life threatening chronic diseases with a high fatality rate and poor prognosis if careful clinical management is
not carried out
Human CE is cosmopolitan and the more common presentation, accounting for most of the estimated two to three million global
echinococcosis cases. AE has an extensive geographical range in the northern hemisphere
Diagnosis is based on clinical findings, imaging (radiology, ultrasonography, computed axial tomography, magnetic resonance imaging),
and serology
Treatment options for CE are: surgery, percutaneous sterilisation, drugs, and observation (watch and wait). Surgery is the basis of
treatment for early AE, but patients not suitable for surgery and those who have had surgical resection of parasite lesions must be
treated with benzimidazoles (albendazole, mebendazole) for several years
Sources and selection criteria
We obtained information from personal reference archives, personal experience, and extensive literature searches of the PubMed and
Cochrane databases. We sourced English language papers that were fully published mainly between 2000 and March 2012 using appropriate
index terms. Keywords included: “Echinococcus”, “Echinococcus granulosus”, “Echinococcus multilocularis”, “echinococcal cysts”, “hydatid
cysts”, “hydatid disease”, “cystic echinococcosis”, “alveolar echinococcosis”, “hydatidosis”, “hydatid”, “surgery”, “liver transplant”, “mebendazole”,
“albendazole”, “benzimidazole”, “chemotherapy”, “PAIR”, “percutaneous treatment”, “percutaneous drainage”, “ultrasound”; and “Echinococcus”
with “diagnosis”, “serology”, “treatment”, “clinical”, “review”, “meta analysis”; and “echinococcosis” with diagnosis”, “serology”, “treatment”,
“clinical”, “review”, and “meta analysis”.
AE generally has a longer latent phase (up to 15 years) before
the onset of chronic disease.1 12 w18 E multilocularis usually
develops in the right liver lobe and AE lesions range from a few
millimetres to 15-20 cm in diameter in areas of infiltration.1 12
Extrahepatic primary disease is uncommon.1 12 w18w19Metastasis
formation leads to secondary AE with infiltration of the lung,
spleen, or brain. Symptoms of AE usually include epigastric
pain or cholestatic jaundice.12
How is echinococcosis diagnosed?
The box shows the best indicators of disease. The diagnosis of
CE is based on clinical findings, imaging results, and
serology.1-3 6 7 11 12 15-17 Clinical manifestations may indicate cyst
rupture, secondary bacterial infection, allergic reactions, or
anaphylaxis.1 17 Patients with symptoms should immediately be
advised to undergo imaging and serology.
Ultrasound is a crucially important tool for the diagnosis,
staging, and follow-up of abdominal CE cysts, although it has
low sensitivity for detecting small cysts. The first generally
accepted ultrasound classification for CE was developed in
1981.w21A series of meetings by aWHO informal working group
on echinococcosis (WHO-IWGE) resulted in an international
standardised ultrasound classification of CE cysts into three
groups (fig 4⇓).6 12 16 Microscopy of cystic fluid for brood
capsules or protoscoleces provides proof of infection and cyst
viability.6 Polymerase chain reaction (PCR) analysis of biopsy
material can also provide a definitive diagnosis.6 High field
magnetic resonance spectroscopy is also useful for determining
cyst viability and for staging.1 w22
CE serology is a helpful diagnostic adjunct and can be used to
monitor patients after surgery or drug treatment. However,
although usedwidely, particularly in developing countries where
imaging techniques may not be readily available, questions
remain with regard to its effectiveness for clinical detection and
screening.17 w23w24 Serum antibodymeasurement is more sensitive
than detection of circulating E granulosus antigens,1 11 w8 but
available tests lack standardisation.11 17 Current serology for
human CE mainly tests for IgG antibodies against native or
recombinant antigen B by enzyme linked immunosorbent assay
or western blotting.2 11 w25 Test specificity is affected by
immunological crossreactivity with antigens found in other
helminth infections, cancers, and liver cirrhosis and by the
presence of anti-P1 antibodies.2 11 Although not thoroughly
tested,17 serodiagnostic performance seems to depend also on
cyst location, cyst size, and stage.
The seriousness of human AE means early detection is crucial
so that treatment can start.1 5 12 Diagnosis is analogous to that
for CE including clinical findings and use of imaging techniques
and serology.1 5 12 Ultrasound is the main diagnostic test for AE
in the abdomen,5 and the imaging based WHO-IWGE PNM
classification system (table 1⇓; fig 5⇓) is the recognised
benchmark for standardised evaluation of diagnosis and
treatment.5 12 18
As with CE, serodiagnosis of AE is used as an adjunct to other
detection procedures.11 w8 w26 w27 Conventional PCR can detect E
multilocularis specific nucleic acids in tissue biopsies and real
time PCR can be used to assess viability.5 w28 w29 Notably,
however, for both diseases a negative real time PCR result does
not reflect complete parasite inactivity and a negative PCR
cannot rule out disease.5 w29
How is CE treated and managed?
TheWHO-IWGE classification provides the basis for choosing
basically four treatment and management options for CE:
surgery, percutaneous sterilisation, drug treatment, and
observation (watch and wait).5 6 17However, there is no optimum
treatment for CE and no clinical trials have compared the
different modalities.5 Table 2⇓ shows the current expert
consensus on the management of liver CE.5
Surgery
Surgery is the classic treatment but, despite being curative, it
does not totally prevent recurrence.5 Furthermore, in the absence
of specific clinical trials, the evidence for the surgical treatment
of complicated liver and disseminated CE is limited.5 w30 Surgery
is, however, the choice for large or infected cysts, cysts likely
to rupture, and cysts in important organ locations.1 5 Surgery
may not be practical for patients with multiple cysts in several
organs.1 5Open cystectomy, pericystectomy, partial hepatectomy
or lobectomy, cyst extrusion (Barrett’s technique), and drainage
of infected cysts are some of the surgical options available.1 In
cases where cyst resection is incomplete, or if small lesions
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Key indicators for a positive diagnosis of echinococcosis
Medical history
Have you travelled to or emigrated from an endemic country (about five to 10 years ago)? If so, from where? (fig 1)
Have you had contact with dogs, foxes, or livestock during the past five to 10 years?
Have you worked in a pastoral area where you may have had contact with wildlife during the past five to 10 years?
Have you worked in an abattoir during the past five to 10 years?
Cystic echinococcosis
Upper abdominal discomfort
Poor appetite
Alveolar echinococcosis
Vague abdominal pain (right upper quadrant; 30% cases) (most cases originate in the liver)
Jaundice (25% cases)
Fatigue, weight loss, fever, chills
Physical examination
Cystic echinococcosis
On palpation of the abdomen a mass may be found on the surface of organs (the liver is affected in two thirds of patients); hepatomegaly
or abdominal distension may also be seen
Chest pain, cough, and haemoptysis can be indicative of cysts in the lung; cyst rupture into the bronchi may result in the expulsion of
hydatid material and cystic membranes
Cyst rupture can induce fever, urticaria, eosinophilia, and anaphylactic shock
Alveolar echinococcosis
On palpation of the abdomen, hepatomegaly may be detected
Splenomegaly may be present in cases complicated by portal hypertension
Collateral circulation between the inferior and superior vena cava may be present on the skin in the thoracic and abdominal regions in
advanced cases
Other physical symptoms are dictated by the location of metastatic legions (see lung involvement for cystic echinococcosis)
Laboratory investigations
General laboratory investigations show non-specific results
Serology can help form a definitive diagnosis
Ultrasound guided fine needle biopsy can also be used to examine hydatid cyst fluid for the presence of protoscoleces or DNA using
molecular techniques (polymerase chain reaction)
Radiology
Ultrasound (figs 4 and 5), computed tomography, and magnetic resonance imaging are the procedures of choice for the definitive
diagnosis of echinococcosis
Imaging should be used to examine not only the liver but also the entire abdomen and thorax, and they are able to determine metastatic
locations in alveolar echinococcosis
remain undetected, disease can recur.1 Postoperative fatality is
about 2% but can be higher if additional surgery is needed or
if medical facilities are inadequate.12 15
Percutaneous sterilisation techniques
These include PAIR (puncture, aspiration, injection,
reaspiration), which destroys the cyst’s germinal layer,w31-w33
and modified catheterisation approaches, which evacuate the
complete cyst.1 5 12 PAIR, developed in the 1980s, involves
ultrasound assisted percutaneous needle puncture aspiration of
the cyst, followed by injection of a suitable protoscolicide (such
as 20% sodium chloride or 95% ethanol) and cyst reaspiration
after 15-20 minutes.1 Anaphylaxis is a risk. Assess cyst fluid
for protoscoleces and bilirubin, and, to minimise the risk of
secondary CE, co-administer benzimidazole. CE2 and CE3b
stages (fig 4) are problematic because they have many
compartments that require individual puncture, and these
commonly relapse after PAIR.17 Large bore catheters, combined
with suitable aspiration equipment, may in future replace PAIR
for these stages,17 but their true effectiveness needs to be
established.5 The choice of between surgery or percutaneous
sterilisation can be difficult. Comparison of the two procedures
requires large carefully designed clinical studies, which have
yet to be done.17
Antiparasite drug treatment
The benzimidazoles—albendazole and mebendazole—are
generally regarded as the most effective drugs for treating
uncomplicated CE cysts and as an alternative to invasive
surgery. Mebendazole was used in the 1970 and 1980s, but
albendazole is now the drug of choice. It is administered in 10
mg/kg doses (usually 400mg) twice daily; mebendazole (40-50
mg/kg a day in three doses) is less effective than albendazole.19
However, studies carried out with both drugs have been small,
and heterogeneity inmethodology has preventedmeta-analysis.17
Furthermore, a recent pooled study of individual data from
patients with CE (six treatment centres; five countries) suggested
that the overall efficacy of these drugs may have been
overstated.20 Systematic randomised controlled trials that
compare standardised treatment with benzimidazoles at different
cyst stages with other options are needed,20 especially as these
drugs seem to work better against some cyst stages (such as
small CE1 cysts). Indeed, benzimidazoles are not effective
against large cysts (>10 cm), being diluted by the volume of
fluid present.5 The degree and type of side effects of sustained
use of benzimidazoles also warrant rigorous study.5
Benzimidazoles should not be used in early pregnancy or against
cysts at risk of rupture.1 5 Thorough assessment of other
anthelmintics (such as praziquantel and nitazoxanide) and
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combinations of anthelmintics (such as albendazole plus
praziquantel) that have been used to treat CE is also needed.w34-w37
Watch and wait
Leaving uncomplicated cyst types (CE4 and CE5) untreated
and just monitoring them by imaging (particularly ultrasound)
is a logical management option given that a proportion of cysts
calcify over time and become completely inactive; such cysts
do not compromise organ function or cause discomfort.15 w38
Such an approach is attractive but requires systematic study to
define fully its indications and limitations.
How is AE treated and managed?
Table 3⇓ details a stage specific approach to treating AE.
Historically, surgery has been the recommended treatment for
early disease.1 5 Early diagnosis reduces the need for radical
surgery and results in fewer unresectable lesions.1 5 Long term
treatment with benzimidazoles is essential for patients with
inoperable AE or after resection of Emultilocularis lesions.1 5 12
Benzimidazoles are parasitostatic—they inhibit larval
proliferation but do not kill metacestodes.w39 They should be
given for a minimum of two years and patients monitored for
at least 10 years for relapse.w40 Benzimidazoles are not
recommended before surgery.5 As for CE, the drugs are given
orally with fat-rich meals (10-l5 mg/kg/day, in two doses),
although they have been given at a higher dose of 20 mg per kg
per day for 4.5 years.5 Continuous treatment with albendazole
is tolerated well, having been used for more than 20 years in
some patients; intermittent use is not recommended.5
Mebendazole, given at a dose of 40-50 mg per kg per day over
three days with a fatty meal, is an alternative to albendazole.5
Figure 6⇓ shows the effect of albendazole treatment on a P4
AE lesion. Neither praziquantel nor nitazoxanide is clinically
effective against AE.5 w41-w43
Allotransplantation of the liver has been carried out in patients
with end stage AE.w44-w46 However, the essential use of
immunosuppressive treatment can stimulate the proliferation
of parasitic remnants in the lung or brain.w45 A long term
prospective follow-up of patients with AE treated by palliative
liver transplantation in the 1980s found that some patients
survived for 20 years.21 Ex vivo liver resection, followed by
autotransplantation of AE-free lateral segments,22 may offer a
radical approach to improving prognosis, but this procedure
needs to be fully evaluated.
What are the future challenges?
Considerable recent progress has been made in the diagnosis,
treatment, and management of echinococcosis, but challenges
remain. Clinical trial data systematically evaluating existing
treatments are not available and ideal treatment options are
lacking. Treatment indicators are often complicated, being based
on cyst characteristics, availability of medical and surgical
expertise and equipment, and patient compliance in long term
monitoring programmes.5
Comparable and standardised procedures and terminology need
to be established by the medical fraternity.5 PAIR should be
undertaken only by experienced doctors and trained teams
capable of managing anaphylactic shock.1 PAIR needs to be
studied systematically, via randomised controlled trials, to assess
its efficacy compared with surgery and other available options
for treatment of uncomplicated hepatic cysts.23
Given recent concerns about the cost and treatment efficacy of
the benzimidazoles,17 new drugs are needed to combat both AE
and CE. Strategies aimed at defining new compounds need to
be pursued.24
TheWHO-IWGEconsensus recommendations for the ultrasound
imaging based classification of CE cysts need to be more wider
disseminated to clinicians because they are useful when choosing
treatment options.5 Similarly, the WHO-IWGE classification
for AE should be advocated as the international classification
because it can help determine whether an Emultilocularis lesion
should be excised or otherwise treated, give some indications
for improved prognosis, and help determine the best treatment
option for the individual patient.5
The current clinical diagnosis of AE and CE relies mainly on
the detection of parasite lesions by imaging methods, but the
procedures are expensive and are generally not available in
resource poor settings. Furthermore, they are not useful for
detecting the early stages of infection, which is a major
disadvantage because earlier diagnosis results in more effective
and successful treatment. Serodiagnosis can play a role in early
detection because specific anti-Echinococcus antibodies appear
in the blood system four to eight weeks after infection. Most
available immunodiagnostic techniques have been used in the
diagnosis of echinococcosis.11However, most of these tests have
not been systematically compared by independent laboratories,
they are mainly used for research purposes, and few have found
general acceptance by clinicians.
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A patient’s perspective
I am a 31 year old farmer of the Hui minority from Ningxia, China. I was first admitted to hospital in May 2003 with extreme fatigue, cough,
and difficulty breathing. A chest radiograph showed that my lungs were scattered with dark shadows and the doctors diagnosed me with a
form of cancer and sent me home. In September 2003 a specialist doctor reviewed my case and asked me to come back to the hospital for
further tests. The specialist doctor asked memany questions, performed a physical examination, and ran some tests including an ultrasound.
The ultrasound and blood test showed that I did not have cancer but had alveolar echinococcosis. The parasite started in my liver and had
spread to my lungs. I was given daily treatment with a drug called albendazole and after six months another chest radiograph showed that
my lungs were clear and I felt much better. I was told to continue taking the drug to stop the parasite spreading from my liver to other organs.
Today I am still taking albendazole and am feeling well.
Zhang Yin Gui, Xiji County, Ningxia Hui Autonomous Region, Peoples’ Republic of China
Tips for non-specialists
Refer symptomatic patients who travelled to, or emigrated from, an echinococcosis endemic area about five to 10 years ago, and had
contact with dogs or wildlife, to an infectious disease physician
Serology provides supportive information for diagnosis but imaging studies provide the definitive diagnosis
Differential diagnosis is important because alveolar echinococcosis often presents with cancer-like symptoms
Imaging studies should examine the entire thorax and abdomen, not just the liver
Treatment may involve the use of drugs (albendazole, mebendazole) or surgery (or both)
Additional educational resources
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US Centers for Disease Control and Prevention (www.dpd.cdc.gov/dpdx/HTML/Echinococcosis.htm)—Description of the Echinococcus
parasites and echinococcosis for professionals, patients, and the public
Patient.co.uk (www.patient.co.uk/doctor/Hydatid-Disease.htm)—Fact sheet of the Echinococcus parasites and echinococcosis for
professionals, patients and the public
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Tables
Table 1| WHO informal working group on echinococcosis PNM classification of alveolar echinococcosis
CharacteristicsPMN
Hepatic localisation of the parasiteP
Primary tumour cannot be assessedPX
No detectable tumour in the liverP0
Peripheral lesions without proximal vascular or biliary involvementP1
Central lesions with proximal vascular or biliary involvement of one lobe*P2
Central lesions with hilar vascular or biliary involvement of both lobes or with involvement of two hepatic veinsP3
Any liver lesion with extension along the vessels† and the biliary treeP4
Extrahepatic involvement of neighbouring organs (diaphragm, lung, pleura, pericardium, heart, gastric and duodenal
wall, adrenal glands, peritoneum, retroperitoneum, parietal wall (muscles, skin, bone), pancreas, regional lymph
nodes, liver ligaments, kidney)
N
Not evaluableNX
No regional involvementN0
Regional involvement of contiguous organs or tissuesN1
The absence or presence of distant metastases (lung, distant lymph nodes, spleen, central nervous system, orbit
of the eye, bone, skin, muscle, kidney, distant peritoneum, retroperitoneum)
M
Not completely evaluatedMX
No metastasis‡M0
MetastasisM1
*For classification, the plane projecting between the bed of the gall bladder and the inferior vena cava divides the liver into two lobes.
†Inferior vena cava, portal vein, and arteries.
‡Negative on chest radiography and cerebral computed tomography.
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Table 2| Suggested stage specific approach to treatment of uncomplicated cystic echinococcosis of the liver. Adapted from Brunetti and
colleagues,5 with permission from Elsevier
Resource settingSuggested treatmentDrug treatmentPercutaneous treatmentSurgeryWHO classification
Optimal<5 cm: albendazoleYesYesNoCE1
Minimal<5 cm: PAIR
Optimal>5 cm: PAIR + albendazole
Minimal>5 cm: PAIR
OptimalOther PT + albendazoleYesYesYesCE2
MinimalOther PT
Optimal<5 cm: albendazoleYesYesNoCE3a
Minimal<5 cm: PAIR
Optimal>5cm: PAIR + albendazole
Minimal>5cm: PAIR
OptimalNon-PAIR PT + albendazoleYesYesYesCE3b
MinimalNon-PAIR PT
Optimal*Watch and waitCE4
Optimal*Watch and waitCE5
*Minimal may not be applicable here because in low resourced remote endemic areas it may be impossible or too expensive to travel to the nearest hospital just
to obtain a diagnosis.
PAIR= puncture, aspiration, injection, reaspiration; PT=percutaneous treatment.
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Table 3| Suggested stage specific approach to treatment of alveolar echinococcosis. Adapted fromBrunetti and colleagues,5 with permission
from Elsevier
Resource settingSuggested treatmentDrug treatment
Interventional
treatmentSurgeryWHO classification
OptimalRadical resection (RO); benzimidazoles for 2 years;
PET/CT controls
YesNoYesP1N0M0
MinimalRadical resection (RO); benzimidazoles for 3 months
OptimalRadical resection (RO); benzimidazoles for 2 yearsYesNoYesP2N0M0
MinimalRadical resection (RO); benzimidazoles for 3 months
OptimalBenzimidazoles continuously; PET/CT /MRI scan initially
and at 2 year intervals
YesNoNoP3N0M0
MinimalBenzimidazoles continuously
OptimalBenzimidazoles continuously; PET/CT/MRI scan initially
and at 2 year intervals
YesYesNoP3N1M0
MinimalSurgery if indicated
OptimalBenzimidazoles continuously; PET/CT/MRI scan initially
and at 2 year intervals
YesYesNoP4N0M0
MinimalSurgery, if indicated
OptimalBenzimidazoles continuously; PET/CT/MRI scan initially
and at 2 year intervals
YesYesNoP4N1M1
MinimalSurgery if indicated
CT=computed tomography; MRI=magnetic resonance imaging; PET=positron emission tomography; RO=complete removal of alveolar echinococcosis lesion.
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Figures
Fig 1 Global distribution of echinococcosis
Fig 2 Life cycles of E granulosus and E multilocularis. Swallowed Echinococcus eggs hatch in the intestine to release
oncospheres which pass through the gut wall and are carried in the blood system to various internal organs where they
develop into hydatid cysts. E granulosus cysts are found mainly in the liver or lungs of humans and intermediate hosts.
Dogs and other canines, which act as definitive hosts for E granulosus, become infected by eating offal with fertile hydatid
cysts containing larval protoscoleces. These larvae evaginate, attach to the canine gut, and develop into sexually mature
adult parasites. Eggs and gravid proglottids are released in faeces. Humans are typically “dead end” hosts, but not always.w20
E multilocularis develops mainly in the liver of humans. Wild carnivores, such as the red fox (Vulpes vulpes) and the arctic
fox (Alopex lagopis) are the major definitive hosts for E multilocularis, with small mammals acting as intermediate hosts.
As with E granulosus, humans are exposed to E multilocularis eggs by handling infected definitive hosts or by eating
contaminated food
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Fig 3 Ultrasound image of simultaneous alveolar (AE) (stage P3) and cystic (CE) (stage CE4) echinococcosis in the right
liver of a patient from the People’s Republic of China
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Fig 4 Ultrasound classification of CE cysts. The WHO informal working group on echinococcosis classification differs from
that of Gharbi and colleaguesw21 by the addition of a “cystic lesion” (CL) stage (undifferentiated) (not shown), and by reversing
the order of CE types 2 and 3. CE3 transitional cysts may be differentiated into CE3a (with detached endocyst) and CE3b
(predominantly solid with daughter vesicles).15 CE1 and CE3a are early stage cysts and CE4 and CE5 late stage cysts
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Fig 5 Staging of AE lesions according to the WHO informal working group on echinococcosis PNM classification system,
based on ultrasound observations. (A) P1; (B) P2; (C) P3; (D) P4; (E) and (F) P4 NO M1—panel E shows primary lesion
in the right liver lobe; panel F shows secondary metastatic lesions in the brain
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CLINICAL REVIEW
Fig 6 Computed tomography scan of the liver showing a large irregular AE lesion in the right lobe containing scattered
calcifications and liquefactions (left panel). After five years of treatment with albendazole, the lesion had not changed in
size but the areas of calcification had increased and those of liquefaction had decreased (right panel)
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